Iterative Health vs Triomics (2026)
Two companies sitting between clinical care and clinical research, reached from opposite directions. Iterative started with computer vision on the colonoscopy feed and has moved decisively toward research acceleration, so a buyer today is engaging with a research organisation that also has a device. Triomics started with the chart, is oncology tuned, holds peer reviewed validation and traces every match back to the pathology and biomarker behind it, delivered where the oncology team already works. For a gastroenterology unit wanting detection, Iterative's shift in emphasis is the thing to weigh, because support and roadmap follow attention. For a cancer centre wanting more patients into trials, Triomics does the eligibility reasoning and Iterative brings the network.
- The detection device sits between the scope and the monitor performing local inference, and the company has shifted decisively toward clinical research alongside it.
- For a health system interested in trial participation as well as detection, the research network is the larger part of what is on offer.
- Gastroenterology is the shared specialty, so a unit evaluating both is comparing within its own service line.
- It is oncology tuned chart abstraction with peer reviewed validation in a recognised journal, tracing every match to the pathology and biomarker that produced it.
- The output lands where the oncology team already works rather than in a separate research tool.
- For a cancer centre, the eligibility reasoning is the constraint rather than the procedure itself.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Iterative Health and Triomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Iterative Health | Triomics |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | Not recorded | 2021 |
| Headquarters | Cambridge, Massachusetts | San Francisco, California |
| Website | iterative.health | triomics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Iterative Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Triomics, Iterative Health grades higher on FDA and Regulatory Status. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Triomics its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Iterative Health, Triomics grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Iterative Health or Triomics?
On the axes where the AI Health Index separates them, Iterative Health grades higher on FDA and Regulatory Status, and Triomics grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Triomics leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Iterative Health and Triomics differ most?
The widest separation the AI Health Index records between Iterative Health and Triomics is on Model and Technology Transparency, where Iterative Health grades C and Triomics grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Iterative Health and Triomics grade the same?
The AI Health Index grades Iterative Health and Triomics the same on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Iterative Health and Triomics not disclosed?
At the last review, at least one of Iterative Health and Triomics published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
These are compared because both sit between a clinical service and a research programme, not because a buyer chooses one over the other. Read the corporate direction on Iterative carefully: the company now presents primarily as a clinical research organisation with its detection device relegated in its own materials, which changes what a purchaser is committing to and how the device is likely to be supported. Neither publishes a false negative rate for the patients its process does not surface, and neither publishes pricing.